Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Neuroscience ; 277: 794-805, 2014 Sep 26.
Article in English | MEDLINE | ID: mdl-25108164

ABSTRACT

The present study investigated the effects of pharmacological spinal inhibition of voltage-gated calcium channels (VGCC) in mouse pruritus. The epidural administration of P/Q-type MVIIC or PhTx3.3, L-type verapamil, T-type NNC 55-0396 or R-type SNX-482 VGCC blockers failed to alter the scratching behavior caused by the proteinase-activated receptor 2 (PAR-2) activator trypsin, injected into the mouse nape skin. Otherwise, trypsin-elicited pruritus was markedly reduced by the spinal administration of preferential N-type VGCC inhibitors MVIIA and Phα1ß. Time-course experiments revealed that Conus magus-derived toxin MVIIA displayed significant effects when dosed from 1h to 4h before trypsin, while the anti-pruritic effects of Phα1ß from Phoneutria nigriventer remained significant for up to 12h. In addition to reducing trypsin-evoked itching, MVIIA or Phα1ß also prevented the itching elicited by intradermal (i.d.) injection of SLIGRL-NH2, compound 48/80 or chloroquine, although they did not affect H2O2-induced scratching behavior. Furthermore, the co-administration of MVIIA or Phα1ß markedly inhibited the pruritus caused by the spinal injection of gastrin-releasing peptide (GRP), but not morphine. Notably, the epidural administration of MVIIA or Phα1ß greatly prevented the chronic pruritus allied to dry skin model. However, either tested toxin failed to alter the edema formation or neutrophil influx caused by trypsin, whereas they significantly reduced the c-Fos activation in laminas I, II and III of the spinal cord. Our data bring novel evidence on itching transmission mechanisms, pointing out the therapeutic relevance of N-type VGCC inhibitors to control refractory pruritus.


Subject(s)
Antipruritics/pharmacology , Calcium Channel Blockers/pharmacology , Calcium Channels, N-Type/metabolism , Pruritus/drug therapy , Spinal Cord/drug effects , Acute Disease , Animals , Chronic Disease , Disease Models, Animal , Dose-Response Relationship, Drug , Male , Mice , Proto-Oncogene Proteins c-fos/metabolism , Pruritus/physiopathology , Skin/immunology , Spider Venoms/pharmacology , Spinal Cord/physiopathology , Time Factors , Trypsin
2.
Anesth Analg ; 91(6): 1479-82, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11094004

ABSTRACT

UNLABELLED: We examined the postoperative analgesia of a controlled delivery ketamine transdermal patch after minor abdominal gynecological surgery using lidocaine epidural blockade. Fifty-two patients were randomized to one of two groups. Epidural anesthesia was performed with 25 mL 2% plain lidocaine. At the end of the surgical procedure, a controlled delivery transdermal patch containing either ketamine (25 mg/24 h) (Ketamine group) or placebo (Placebo group) was applied. Pain and adverse effects were assessed hourly postoperatively for 24 h. IM dipyrone was available at patient request. The two groups were demographically similar. The time to first rescue analgesic was longer in the Ketamine group (230+/-112 min) compared with the Placebo group (94+/-54 min); (P<0.00001). There were more dipyrone dose injections in 24 h in the Placebo group compared with the Ketamine group (P<0.0001). The incidence of adverse effects was similar between groups. We conclude that the transdermal-controlled delivery of ketamine prolonged the duration of analgesia after minor gynecological procedures. IMPLICATIONS: Transdermal delivery of ketamine was an useful adjuvant to postoperative analgesia after epidural lidocaine blockade in the population studied.


Subject(s)
Analgesia, Epidural , Anesthetics, Local , Excitatory Amino Acid Antagonists/administration & dosage , Excitatory Amino Acid Antagonists/therapeutic use , Gynecologic Surgical Procedures , Ketamine/administration & dosage , Ketamine/therapeutic use , Lidocaine , Pain, Postoperative/drug therapy , Administration, Cutaneous , Adult , Blood Pressure/drug effects , Female , Humans , Pain Measurement
3.
Anesth Analg ; 83(4): 766-70, 1996 Oct.
Article in English | MEDLINE | ID: mdl-8831318

ABSTRACT

The purpose of this study was to determine whether intravenous (i.v.) ketamine would enhance analgesia from intrathecal (IT) neostigmine compared with combining i.v. fentanyl with IT neostigmine. Sixty patients undergoing vaginoplasty under spinal anesthesia were assigned to one of six groups (n = 10). Patients were premedicated with midazolam plus the i.v. test drug. The IT drugs were 20 mg bupivacaine plus saline or 50 micrograms neostigmine. The control group (CG) received saline i.v. and IT. The neostigmine control group (NCG) received saline i.v. and neostigmine IT. The ketamine group (KG) received ketamine 0.2 mg/kg i.v. and saline IT, and the ketamine neostigmine group (KNG), ketamine i.v. and neostigmine IT. The fentanyl group (FG) received fentanyl 1 microgram/kg i.v. and saline IT, and the fentanyl neostigmine group (FNG), fentanyl i.v. and neostigmine IT. The time to first rescue analgesic was longer for the FNG and KNG compared with the CG, with less rescue analgesic consumption (P < 0.02 and P < 0.01, respectively). Only the FNG had significantly intraoperative nausea/vomiting (P < 0.02). In conclusion, the combination of i.v. ketamine and IT neostigmine results in prolonged postoperative analgesia and less intraoperative nausea and vomiting than the combination of i.v. fentanyl and IT neostigmine.


Subject(s)
Analgesia , Analgesics, Opioid/administration & dosage , Anesthesia, Spinal , Anesthetics, Dissociative/administration & dosage , Anesthetics, Intravenous/administration & dosage , Cholinesterase Inhibitors/administration & dosage , Fentanyl/administration & dosage , Ketamine/administration & dosage , Neostigmine/administration & dosage , Pain, Postoperative/prevention & control , Analgesics, Opioid/adverse effects , Analgesics, Opioid/pharmacology , Anesthetics, Dissociative/adverse effects , Anesthetics, Dissociative/pharmacology , Anesthetics, Intravenous/adverse effects , Anesthetics, Intravenous/pharmacology , Bupivacaine/administration & dosage , Cholinesterase Inhibitors/adverse effects , Cholinesterase Inhibitors/pharmacology , Drug Synergism , Drug Therapy, Combination , Female , Fentanyl/adverse effects , Fentanyl/pharmacology , Humans , Injections, Spinal , Intraoperative Complications/chemically induced , Ketamine/adverse effects , Ketamine/pharmacology , Nausea/chemically induced , Neostigmine/adverse effects , Neostigmine/pharmacology , Time Factors , Vagina/surgery , Vomiting/chemically induced
SELECTION OF CITATIONS
SEARCH DETAIL
...